Hepatoid Adenocarcinoma of the Lung: Greifswald Diagnostic Criteria

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039195

Enrollment

Registered

2026-02-19

Start date

2025-09-10

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatoid adenocarcinoma of the lung C22.0

Interventions

Group 1: Patients diagnosed with hepatoid adenocarcinoma of the lung (HAL) between January 2012 and December 2024 at the Institute of Pathology, University Medicine Greifswald. Within the scope of thi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: For the planned study, all patients diagnosed with hepatoid adenocarcinoma of the lung between 2012 and 2024 will be included. Additionally, an equal number of gender- and age-matched (± 2 years) patients with hepatocellular carcinoma, who were also diagnosed at the Institute of Pathology in Greifswald, will be incorporated into the analysis. All patients included in this study had either a moderately or poorly differentiated adeno- or hepatocellular carcinoma (tumors of grade II and III according to WHO classification).

Exclusion criteria

Exclusion criteria: No additional exclusion criteria apply for HAL patients. For the hepatocellular carcinoma control group, patients with severe concomitant malignant or chronic diseases will be excluded to ensure a more homogeneous study cohort.

Design outcomes

Primary

Measure	Time frame
What: Identification and validation of specific histomorphological, immunohistochemical, and molecular genetic features enabling reliable discrimination between hepatoid adenocarcinoma of the lung (HAL) and hepatocellular carcinoma (HCC), in accordance with the Greifswald diagnostic criteria. When: Assessed once within the scope of the retrospective analysis, corresponding to the time point of the original pathological diagnosis; no longitudinal follow-up is performed. How: By systematic evaluation of archived histological specimens, immunohistochemical marker profiles, and molecular genetic analyses using next-generation sequencing (NGS) performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks obtained during routine diagnostics. No questionnaires or study-specific scoring instruments are used.	—

Measure

Time frame

What: Identification and validation of specific histomorphological, immunohistochemical, and molecular genetic features enabling reliable discrimination between hepatoid adenocarcinoma of the lung (HAL) and hepatocellular carcinoma (HCC), in accordance with the Greifswald diagnostic criteria. When: Assessed once within the scope of the retrospective analysis, corresponding to the time point of the original pathological diagnosis; no longitudinal follow-up is performed. How: By systematic evaluation of archived histological specimens, immunohistochemical marker profiles, and molecular genetic analyses using next-generation sequencing (NGS) performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks obtained during routine diagnostics. No questionnaires or study-specific scoring instruments are used.

—

Secondary

Measure	Time frame
What: Assessment of clinicopathological parameters (e.g. tumor stage, metastatic status, treatment response, and survival) and their association with histological and molecular findings. When: Retrospectively over the available clinical observation period. How: By systematic review of existing medical records and electronic patient files.	—

Countries

Germany

Contacts

Public ContactShabnam Asadikomeleh

Universitätsmedizin Greifswald, Institut für Pathologie

Shabnam.Asadikomeleh@med.uni-greifswald.de+49 03834 86-57 05

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026